Reading The Pharma Tea Leaves: China Market Heating Up
This article was originally published in PharmAsia News
Executive Summary
Three joint ventures, a U.S.-listed firm to go private, an R&D center expansion and one resignation – all in a week are signs that the China pharma market continues to be dynamic with no signs of letting up.
You may also be interested in...
Alliance Boots Taps Retired Zuellig Pharma CEO to Lead Asia Operation, With M&A On The Mind
Major UK pharmaceutical and beauty products distributor Alliance Boots announced the appointment of retired Zuellig Pharma CEO Fritz Horlacher to head its heathcare division in Asia. The company aims to expand in Asia, especially in Thailand and Korea, which will pose a big challenge to Zuellig and other heavyweight pharmaceutical distributors
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.